Lawsuits, Just the Cost of Criminal Marketing of Antipsychotic Drugs

"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.” Continue reading →

Making a Killing–Marketing Exercises by Dr. Carl Elliott

The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research. Continue reading →

In Medicine, the Power of No vs. Psychiatry’s Mass Overtreatment

Unlike patients in other fields of medicine, those  who are designated mentally ill–or even declared to be "at risk" for mental illness in the future–are at once stigmatized and suffer losss of their autonomy.
Continue reading →

DSM5 Revisions

"Anything you put in that book, any little change you make, has huge implications not only for psychiatry but for pharmaceutical marketing, research, for the legal system, for who’s considered to be normal or not, for who’s considered disabled," said Dr. Michael First, professor of psychiatry at Columbia University who edited the DSM4l but is not involved in the DSM5.

Continue reading →

Is FDA Bipolar or Complicit in Legitimizing Illegal Marketing?

The FDA’s expanded marketing approval process for antipsychotics, highly toxic drugs, is unaffected by evidence uncovered by the US Justice Department showing that the studies submitted by drug manufacturers were often flawed, if not fraudulent. Continue reading →